Reset filter
Keywords
Peripheral Arterial Disease ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
    1. 7.1. Anesthesiology
    1. 7.2. Dermatology
    1. 7.3. ENT
    1. 7.4. Geriatrics
    1. 7.5. Gynecology/Obstetrics
    1. 7.6. Internal Medicine
      1. Hematology
      1. Infectious Diseases
      1. Cardiology/Angiology
      1. Pneumology
      1. Gastroenterology
      1. Nephrology
      1. Endocrinology/Metabolic Diseases
      1. Rheumatology
    1. 7.7. Neurology
    1. 7.8. Ophthalmology
    1. 7.9. Palliative Care
    1. 7.10. Pathology/Forensics
    1. 7.11. Pediatrics
    1. 7.12. Psychiatry/Psychosomatics
    1. 7.13. Radiology
    1. 7.14. Surgery
      1. General/Visceral Surgery
      1. Neurosurgery
      1. Plastic Surgery
      1. Thoracic Surgery
      1. Trauma/Orthopedics
      1. Vascular Surgery
    1. 7.15. Urology
    1. 7.16. Dental Medicine/OMS
Selected data models

You must log in to select data models for download or further analysis.

27 Search results.
Relevance Rating New first Old first

Eligibility Peripheral Arterial Disease NCT00831090

- 8/27/18 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Endothelial Function and Vein Graft Remodeling; ODM derived from: https://clinicaltrials.gov/show/NCT00831090

Eligibility Peripheral Arterial Disease NCT00781950

- 8/27/18 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00781950

Eligibility NCT01094678 Peripheral Arterial Disease - Eligibility

- 4/17/14 - 1 form, 2 itemgroups, 6 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01094678

Eligibility NCT01442636 Peripheral Arterial Disease - Eligibility

- 4/13/14 - 1 form, 4 itemgroups, 61 items, 2 languages
Itemgroups: Inclusion Criteria, Angiographic Inclusion Criteria, Exclusion Criteria, Medical Concepts
ODM derived from http://clinicaltrials.gov/show/NCT01442636

Eligibility NCT01157871 Peripheral Arterial Occlusive Disease - Eligibility

- 9/27/21 - 1 form, 2 itemgroups, 16 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01157871

Peripheral Atherosclerotic Vascular Disease EHR key data elements - Peripheral Atherosclerotic Disease (PAD) - General data elements

- 9/20/21 - 1 form, 5 itemgroups, 103 items, 2 languages
Itemgroups: Demographics, Patient history, Physical evaluation, Laboratory Procedures, Current pharmacologic therapy
2012 ACCF / AHA Data Standard Peripheral Atherosclerotic Disease (PAD) General data elements see http://www.ncbi.nlm.nih.gov/pubmed/22144570

Eligibility NCT01179984 Peripheral Vascular Disease - Eligibility

- 9/27/21 - 1 form, 2 itemgroups, 25 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01179984

EUROASPIRE III - Peripheral arterial occlusive disease Patient Interview Questionnaire - Peripheral arterial occlusive disease Patient Interview Questionnaire

- 8/11/16 - 1 form, 6 itemgroups, 69 items, 1 language
Itemgroups: Demographic Information, Smoking, Risk factor awareness and targets, Lifestyle changes, Family history of cardiovascular disease, General Health assessment
Provided by Prof. Keil Source: Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 Mar 14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-5. PubMed PMID: 19286092

Eligibility Vascular Stent in Peripheral Artery Disease DRKS00006281 NCT02262949 DRKS00006281 - Eligibility Vascular Stent in Peripheral Artery Disease NCT02262949 DRKS00006281

- 6/25/17 - 1 form, 2 itemgroups, 26 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: C. R. Bard ClinicalTrials.gov Identifier: NCT02262949 History of Changes Other Study ID Numbers: BPV-13-002 DRKS00006281 ( Registry Identifier: Deutsches Register Klinischer Studien ) Study First Received: September 25, 2014 Last Updated: December 6, 2016 A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System (REALITY2) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT02262949

dbGaP phs001345 NHLBI TOPMed: Genetic Epidemiology Network of Arteriopathy (GENOA) - Eligibility

- 3/5/23 - 4 forms, 1 itemgroup, 6 items, 1 language
Itemgroup: IG.elig
Principal Investigator: Sharon L.R. Kardia, PhD, University of Michigan, Ann Arbor, MI, USA MeSH: Hypertension,Aging,Arterial Pressure,Arteriosclerosis,Atherosclerosis,Biomarkers,Blood Pressure,Cardiovascular Diseases,Cholesterol,Cholesterol, HDL,Cholesterol, LDL,Coronary Artery Disease,Diabetes Mellitus,Echocardiography,Endophenotypes,Hyperglycemia,Hyperinsulinism,Hypertrophy, Left Ventricular,Inflammation,Kidney Failure, Chronic,Leukoaraiosis,Lipids,Obesity,Obesity, Abdominal,Peripheral Arterial Disease,Renal Insufficiency, Chronic,Triglycerides,Vascular Calcification https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001345 The Genetic Epidemiology Network of Arteriopathy (GENOA) is one of four networks in the NHLBI Family-Blood Pressure Program (FBPP). GENOA's long-term objective is to elucidate the genetics of target organ complications of hypertension, including both atherosclerotic and arteriolosclerotic complications involving the heart, brain, kidneys, and peripheral arteries. The longitudinal GENOA Study recruited European-American and African-American sibships with at least 2 individuals with clinically diagnosed essential hypertension before age 60 years. All other members of the sibship were invited to participate regardless of their hypertension status. Participants were diagnosed with hypertension if they had either 1) a previous clinical diagnosis of hypertension by a physician with current anti-hypertensive treatment, or 2) an average systolic blood pressure = 140 mm Hg or diastolic blood pressure = 90 mm Hg based on the second and third readings at the time of their clinic visit. Only participants of the African-American Cohort were sequenced through TOPMed. The Family Blood Pressure Program (FBPP), GENOA's parent program, is an unprecedented collaboration to identify genes influencing blood pressure (BP) levels, hypertension, and its target-organ damage. This program has conducted over 21,000 physical examinations, assembled a shared database of several hundred BP and hypertension-related phenotypic measurements, completed genome-wide linkage analyses for BP, hypertension, and hypertension associated risk factors and complications, and published over 130 manuscripts on program findings. The FBPP emerged from what was initially funded as four independent networks of investigators (HyperGEN, GenNet, SAPPHIRe and GENOA) competing to identify genetic determinants of hypertension in multiple ethnic groups. Realizing the greater likelihood of success through collaboration, the investigators created a single confederation with program-wide and network-specific goals. Comprehensive phenotypic data for GENOA study participants are available through dbGaP phs001238.

pht008602.v1.p1

1 itemgroup 4 items

pht008603.v1.p1

1 itemgroup 2 items

pht008604.v1.p1

1 itemgroup 10 items

Peripheral Atherosclerotic Disease (PAD) - Lower Extremity data elements

- 4/13/21 - 1 form, 10 itemgroups, 57 items, 2 languages
Itemgroups: Signs and Symptoms, Physical evaluation, Diagnostics, noninvasive, Diagnostics, invasive, Pharmacological Therapy Claudication, Exercise Program, Therapeutic Procedures, Procedure Outcomes, Clinical Outcomes, Cardiovascular Outcomes
2012 ACCF / AHA Data Standard Peripheral Atherosclerotic Disease (PAD) Lower Extremity data elements see http://www.ncbi.nlm.nih.gov/pubmed/22144570

Screening: Inclusion criteria Nicotinsäure und Naftidrofuryl bei pAVK-Patienten nach Angioplastie - Screening: Inclusion criteria Nicotinsäure und Naftidrofuryl bei pAVK-Patienten nach Angioplastie

- 8/22/16 - 1 form, 2 itemgroups, 7 items, 1 language
Itemgroups: Identification, Inclusion
Leiter der Klinischen Prüfung: PD. Dr. med. Knut Kröger Klinik für Angiologie Universitätsklinikum Essen Hufelandstr. 55 45122 Essen Telefon: 0201/723-2530 Fax: 0201/723-5967 Sponsor: Universitätsklinikum Essen Hufelandstraße 55 45122 Essen Datenmanagement und Biometrie C. Ose und Chr. Lösch Zentrum für Klinische Studien Essen Leiter: Prof. Dr. K.-H. Jöckel Hufelandstr. 55, 45122 Essen Universitätsklinikum Essen Telefon.: 0201/723-4519 Fax: 0201/723-5933 E-Mail: claudia.ose@uk-essen.de Screening: Inclusion criteria

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial